The lectin pathway of complement: Advantage or disadvantage in HIV pathogenesis?

Clinical Immunology

Volumn 154, Issue 1, 2014, Pages 13-25

  Ballegaard, V ^a   Haugaard, A K ^a   Garred, P ^a   Nielsen, S D ^a   Munthe Fog, L ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Collectin 11; Ficolin 1, 2 and 3; HIV; Innate immunity; Lectin pathway; Mannose binding lectin (MBL)

Indexed keywords

COLLECTIN; COLLECTIN 11; FICOLIN; FICOLIN 1; FICOLIN 2; FICOLIN 3; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT LECTIN PATHWAY; DISEASE COURSE; DISEASE TRANSMISSION; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

COLLECTIN-11; FICOLIN-1, -2 AND -3; HIV; INNATE IMMUNITY; LECTIN PATHWAY; MANNOSE-BINDING LECTIN (MBL);

COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC;

EID: 84903772132     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.06.002     Document Type: Review

References (128)

1. Yu Q., Yu R., Qin X. The good and evil of complement activation in HIV-1 infection. Cell. Mol. Immunol. 2010, 7:334-340.
2. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990, 265:10373-10382.
3. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
4. Korkut A., Hendrickson W.A. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120. PLoS One 2012, 7:e52170.
5. Saifuddin M., Hart M.L., Gewurz H., Zhang Y., Spear G.T. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J. Gen. Virol. 2000, 81:949-955.
6. Ezekowitz R.A., Kuhlman M., Groopman J.E., Byrn R.A. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J. Exp. Med. 1989, 169:185-196.
7. Hart M.L., Saifuddin M., Uemura K., Bremer E.G., Hooker B., Kawasaki T., et al. High mannose glycans and sialic acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1. AIDS Res. Hum. Retroviruses 2002, 18:1311-1317.
8. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
9. Dunkelberger J.R., Song W.-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
10. Peng Q., Li K., Sacks S.H., Zhou W. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm. Allergy Drug Targets 2009, 8(3):236-246.
11. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115-149.
12. Petersen S.V., Thiel S., Jensenius J.C. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 2001, 38:133-149.
13. Endo Y., Matsushita M., Fujita T. The role of ficolins in the lectin pathway of innate immunity. Int. J. Biochem. Cell Biol. 2011, 43:705-712.
14. Ma Y.J., Skjoedt M.-O., Garred P. Collectin-11/MASP complex formation triggers activation of the lectin complement pathway - the fifth lectin pathway initiation complex. J. Innate Immun. 2012, 5(3):242-250.
15. Garred P., Larsen F., Seyfarth J., Fujita R., Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7:85-94.
16. Garred P., Honoré C., Ma Y.J., Munthe-Fog L., Hummelshøj T. MBL2, FCN1, FCN2 and FCN3-the genes behind the initiation of the lectin pathway of complement. Mol. Immunol. 2009, 46:2737-2744.
17. Munthe-Fog L., Hummelshoj T., Honoré C., Moller M.E., Skjoedt M.O., Palsgaard I., et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun. 2012, 13:515-522.
18. Munthe-Fog L., Hummelshøj T., Hansen B.E., Koch C., Madsen H.O., Skjødt K., et al. The impact of FCN2 polymorphisms and haplotypes on the ficolin-2 serum levels. Scand. J. Immunol. 2007, 65:383-392.
19. Munthe-Fog L., Hummelshøj T., Ma Y.J., Hansen B.E., Koch C., Madsen H.O., et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a ficolin-3 (Hakata antigen) deficiency state. Mol. Immunol. 2008, 45:2660-2666.
20. Hummelshoj T., Fog L.M., Madsen H.O., Sim R.B., Garred P. Comparative study of the human ficolins reveals unique features of ficolin-3 (Hakata antigen). Mol. Immunol. 2008, 45:1623-1632.
21. Hummelshoj T., Munthe-Fog L., Madsen H.O., Fujita T., Matsushita M., Garred P. Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum. Mol. Genet. 2005, 14:1651-1658.
22. Ma Y.J., Doni A., Hummelshøj T., Honoré C., Bastone A., Mantovani A., et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J. Biol. Chem. 2009, 284:28263-28275.
23. Munthe-Fog L., Hummelshøj T., Honoré C., Madsen H.O., Permin H., Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N. Engl. J. Med. 2009, 360:2637-2644.
24. Schlapbach L.J., Thiel S., Kessler U., Ammann R.A., Aebi C., Jensenius J.C. Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut 2011, 60:1438-1439.
25. Selman L., Hansen S. Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1). Immunobiology 2012, 217(9):851-863.
26. Selman L., Henriksen M.L., Brandt J., Palarasah Y., Waters A., Beales P.L., et al. An enzyme-linked immunosorbent assay (ELISA) for quantification of human collectin 11 (CL-11, CL-K1). J. Immunol. Methods 2012, 375:182-188.
27. Rooryck C., Diaz-Font A., Osborn D.P.S., Chabchoub E., Hernandez-Hernandez V., Shamseldin H., et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat. Genet. 2011, 43:197-203.
28. Axelgaard E., Jensen L., Dyrlund T.F., Nielsen H.J., Enghild J.J., Thiel S., et al. Investigations on collectin liver 1. J. Biol. Chem. 2013, 288:23407-23420.
29. Jack D.L., Turner M.W. Anti-microbial activities of mannose-binding lectin. Biochem. Soc. Trans. 2003, 31:753-757.
30. Heitzeneder S., Seidel M., Förster-Waldl E., Heitger A. Mannan-binding lectin deficiency - good news, bad news, doesn't matter?. Clin. Immunol. 2012, 143:22-38.
31. Wiertsema S.P., Herpers B.L., Veenhoven R.H., Salimans M.M.M., Ruven H.J.T., Sanders E.A.M., et al. Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. J. Allergy Clin. Immunol. 2006, 117:1344-1350.
32. Cedzynski M., Atkinson A.P.M., St Swierzko A., MacDonald S.L., Szala A., Zeman K., et al. L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in children. Mol. Immunol. 2009, 47:415-419.
33. Chen J., Xu Z., Ou X., Wang M., Yang X., Li Q. Mannose-binding lectin polymorphisms and recurrent respiratory tract infection in Chinese children. Eur. J. Pediatr. 2009, 168:1305-1313.
34. Koch A., Melbye M., Sørensen P., Homøe P., Madsen H.O., Mølbak K., et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001, 285:1316-1321.
35. Peterslund N.A., Koch C., Jensenius J.C., Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001, 358:637-638.
36. Osthoff M., Rovó A., Stern M., Danner D., Gratwohl A., Tichelli A., et al. Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation. Haematologica 2010, 95:1389-1396.
37. Neth O., Hann I., Turner M.W., Klein N.J. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001, 358:614-618.
38. Dommett R., Chisholm J., Turner M., Bajaj-Elliott M., Klein N.J. Mannose-binding lectin genotype influences frequency and duration of infectious complications in children with malignancy. J. Pediatr. Hematol. Oncol. 2013, 35:69-75.
39. Garred P., Madsen H.O., Hofmann B., Svejgaard A. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995, 346:941-943.
40. Chalmers J.D., Fleming G.B., Hill A.T., Kilpatrick D.C. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011, 21:271-282.
41. Roy S., Knox K., Segal S., Griffiths D., Moore C.E., Welsh K.I., et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002, 359:1569-1573.
42. García-Laorden M.I., Rodríguez de Castro F., Solé-Violán J., Payeras A., Briones M.L., Borderías L., et al. The role of mannose-binding lectin in pneumococcal infection. Eur. Respir. J. 2013, 41:131-139.
43. Eisen D.P., Dean M.M., Boermeester M.A., Fidler K.J., Gordon A.C., Kronborg G., et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin. Infect. Dis. 2008, 47:510-516.
44. Bax W.A., Cluysenaer O.J., Bartelink A.K., Aerts P.C., Ezekowitz R.A., van Dijk H. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 1999, 354:1094-1095.
45. Faber J., Schuessler T., Finn A., Murdoch C., Zenz W., Habermehl P., et al. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr. Infect. Dis. J. 2007, 26:243-246.
46. Kuipers S., Aerts P.C., Cluysenaer O.J.J., Bartelink A.K.M., Ezekowitz R.A.B., Bax W.A., et al. A case of familial meningococcal disease due to deficiency in mannose-binding lectin (MBL). Adv. Exp. Med. Biol. 2003, 531:351-355.
47. Hibberd M.L., Sumiya M., Summerfield J.A., Booy R., Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999, 353:1049-1053.
48. Brown K.S., Ryder S.D., Irving W.L., Sim R.B., Hickling T.P. Mannan binding lectin and viral hepatitis. Immunol. Lett. 2007, 108:34-44.
49. Thio C.L., Mosbruger T., Astemborski J., Greer S., Kirk G.D., O'Brien S.J., et al. Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J. Virol. 2005, 79:9192-9196.
50. Song L.H., Binh V.Q., Duy D.N., Jüliger S., Bock T.C., Luty A.J.F., et al. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat. Res. 2003, 522:119-125.
51. Yuen M.F., Lau C.S., Lau Y.L., Wong W.M., Cheng C.C., Lai C.L. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999, 29:1248-1251.
52. Chong W.P., To Y.F., Ip W.K., Yuen M.F., Poon T.P., Wong W.H.S., et al. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005, 42:1037-1045.
53. Hakozaki Y., Yoshiba M., Sekiyama K., Seike E., Iwamoto J., Mitani K., et al. Mannose-binding lectin and the prognosis of fulminant hepatic failure caused by HBV infection. Liver 2002, 22:29-34.
54. Anders E.M., Hartley C.A., Reading P.C., Ezekowitz R.A. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin. J. Gen. Virol. 1994, 75(Pt 3):615-622.
55. Kase T., Suzuki Y., Kawai T., Sakamoto T., Ohtani K., Eda S., et al. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology 1999, 97:385-392.
56. Chang W.-C., White M.R., Moyo P., McClear S., Thiel S., Hartshorn K.L., et al. Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol. 2010, 11:64.
57. Brudner M., Karpel M., Lear C., Chen L., Yantosca L.M., Scully C., et al. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 2013, 8:e60838.
58. Honoré C., Rørvig S., Hummelshøj T., Skjoedt M.-O., Borregaard N., Garred P. Tethering of ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J. Leukoc. Biol. 2010, 88:145-158.
59. Kjaer T.R., Hansen A.G., Sørensen U.B.S., Nielsen O., Thiel S., Jensenius J.C. Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J. Leukoc. Biol. 2011, 90:425-437.
60. Swierzko A.S., Atkinson A.P.M., Cedzynski M., Macdonald S.L., Szala A., Domzalska-Popadiuk I., et al. Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates. Mol. Immunol. 2009, 46:551-558.
61. Messias Reason I.J., Schafranski M.D., Jensenius J.C., Steffensen R. The association between mannose-binding lectin gene polymorphism and rheumatic heart disease. Hum. Immunol. 2006, 67:991-998.
62. Pan Q., Chen H., Wang F., Jeza V.T., Hou W., Zhao Y., et al. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J. Innate Immun. 2012, 4:312-324.
63. Chang W.-C., Hartshorn K.L., White M.R., Moyo P., Michelow I.C., Koziel H., et al. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem. Pharmacol. 2011, 81:388-395.
64. Takahashi K., Moyo P., Chigweshe L., Chang W.-C., White M.R., Hartshorn K.L. Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res. 2013, 178:495-501.
65. Liu J., Ali M.A.M., Shi Y., Zhao Y., Luo F., Yu J., et al. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell. Mol. Immunol. 2009, 6:235-244.
66. Hu Y.-L., Luo F.-L., Fu J.-L., Chen T.-L., Wu S.-M., Zhou Y.-D., et al. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand. J. Immunol. 2013, 77:144-150.
67. Hoang T.V., Toan N.L., Song L.H., Ouf E.A., Bock C.-T., Kremsner P.G., et al. Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One 2011, 6:e28113.
68. Manuel O., Pascual M., Trendelenburg M., Meylan P.R. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007, 83:359-362.
69. de Rooij B.-J.F., van der Beek M.T., van Hoek B., Vossen A.C.T.M., Rogier Ten Hove W., Roos A., et al. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J. Hepatol. 2011, 55:800-807.
70. Egli A., Schäfer J., Osthoff M., Thiel S., Mikkelsen C., Rauch A., et al. Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One 2013, 8:e51983.
71. Ouf E.A., Ojurongbe O., Akindele A.A., Sina-Agbaje O.R., Van Tong H., Adeyeba A.O., et al. Ficolin-2 levels and FCN2 genetic polymorphisms as a susceptibility factor in schistosomiasis. J. Infect. Dis. 2012, 206:562-570.
72. Luz P.R., Boldt A.B.W., Grisbach C., Kun J.F.J., Velavan T.P., Messias-Reason I.J.T. Association of L-ficolin levels and FCN2 genotypes with chronic Chagas disease. PLoS One 2013, 8:e60237.
73. Verma A., White M., Vathipadiekal V., Tripathi S., Mbianda J., Ieong M., et al. Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J. Immunol. 2012, 189(5):2478-2487.
74. Schlapbach L.J., Mattmann M., Thiel S., Boillat C., Otth M., Nelle M., et al. Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin. Infect. Dis. 2010, 51:153-162.
75. Hansen S., Selman L., Palaniyar N., Ziegler K., Brandt J., Kliem A., et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J. Immunol. 2010, 185:6096-6104.
76. Saifuddin M., Hedayati T., Atkinson J.P., Holguin M.H., Parker C.J., Spear G.T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 1997, 78(Pt 8):1907-1911.
77. Schmitz J., Zimmer J.P., Kluxen B., Aries S., Bögel M., Gigli I., et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J. Clin. Invest. 1995, 96:1520-1526.
78. Keele B.F., Tazi L., Gartner S., Liu Y., Burgon T.B., Estes J.D., et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 2008, 82:5548-5561.
79. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.A., Melroe H., et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989.
80. Spear G.T., Takefman D.M., Sullivan B.L., Landay A.L., Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 1993, 67:53-59.
81. Gregersen J.P., Mehdi S., Baur A., Hilfenhaus J. Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J. Med. Virol. 1990, 30:287-293.
82. Soederholm A., Bánki Z., Wilflingseder D., Gassner C., Zwirner J., López-Trascasa M., et al. HIV-1 induced generation of C5a attracts immature dendritic cells and promotes infection of autologous T cells. Eur. J. Immunol. 2007, 37:2156-2163.
83. Kacani L., Bánki Z., Zwirner J., Schennach H., Bajtay Z., Erdei A., et al. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J. Immunol. 2001, 166:3410-3415.
84. Nielsen S.D., Sørensen A.M., Schønning K., Lund O., Nielsen J.O., Hansen J.E. Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. Scand. J. Infect. Dis. 1997, 29:447-452.
85. Ji X., Gewurz H., Spear G.T. Mannose binding lectin (MBL) and HIV. Mol. Immunol. 2005, 42:145-152.
86. Ying H., Ji X., Hart M.L., Gupta K., Saifuddin M., Zariffard M.R., et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res. Hum. Retroviruses 2004, 20:327-335.
87. Haurum J.S., Thiel S., Jones I.M., Fischer P.B., Laursen S.B., Jensenius J.C. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993, 7:1307-1313.
88. Saarloos M.N., Lint T.F., Spear G.T. Efficacy of HIV-specific and "antibody-independent" mechanisms for complement activation by HIV-infected cells. Clin. Exp. Immunol. 1995, 99:189-195.
89. Hart M.L., Saifuddin M., Spear G.T. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J. Gen. Virol. 2003, 84:353-360.
90. Marzi A., Mitchell D.A., Chaipan C., Fisch T., Doms R.W., Carrington M., et al. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology 2007, 368:322-330.
91. Heggelund L., Mollnes T.E., Espevik T., Müller F., Kristiansen K.I., Aukrust P., et al. Modulatory effect of mannose-binding lectin on cytokine responses: possible roles in HIV infection. Eur. J. Clin. Invest. 2005, 35:765-770.
92. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
93. + T lymphocytes. J. Immunol. 2007, 178:3177-3185.
94. Lee B., Leslie G., Soilleux E., O'Doherty U., Baik S., Levroney E., et al. cis expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J. Virol. 2001, 75:12028-12038.
95. Spear G.T., Zariffard M.R., Xin J., Saifuddin M. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 2003, 110:80-85.
96. Singh K.K., Nathamu S., Adame A., Alire T.U., Dumaop W., Gouaux B., et al. Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. J. Neurobehav. HIV Med. 2011, 3:41-52.
97. Garred P., Madsen H.O., Balslev U., Hofmann B., Pedersen C., Gerstoft J., et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997, 349:236-240.
98. Pastinen T., Liitsola K., Niini P., Salminen M., Syvänen A.C. Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res. Hum. Retroviruses 1998, 14:695-698.
99. Sheng A., Lan J., Wu H., Lu J., Wang Y., Chu Q., et al. A clinical case-control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. Int. J. Immunogenet. 2010, 37:445-454.
100. da Silva G.K., Guimarães R., Mattevi V.S., Lazzaretti R.K., Sprinz E., Kuhmmer R., et al. The role of mannose-binding lectin gene polymorphisms in susceptibility to HIV-1 infection in Southern Brazilian patients. AIDS 2011, 25:411-418.
101. Chatterjee A., Rathore A., Yamamoto N., Dhole T.N. Mannose-binding lectin (+54) exon-1 gene polymorphism influence human immunodeficiency virus-1 susceptibility in North Indians. Tissue Antigens 2011, 77:18-22.
102. Tan Y., Liu L., Luo P., Wang A., Jia T., Shen X., et al. Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol. Immunol. 2009, 47:632-638.
103. Amoroso A., Berrino M., Boniotto M., Crovella S., Palomba E., Scarlatti G., et al. Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. AIDS 1999, 13:863-864.
104. Boniotto M., Crovella S., Pirulli D., Scarlatti G., Spanò A., Vatta L., et al. Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun. 2000, 1:346-348.
105. Boniotto M., Braida L., Pirulli D., Arraes L., Amoroso A., Crovella S. MBL2 polymorphisms are involved in HIV-1 infection in Brazilian perinatally infected children. AIDS 2003, 17:779-780.
106. Kuhn L., Coutsoudis A., Trabattoni D., Archary D., Rossi T., Segat L., et al. Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers. Am. J. Clin. Nutr. 2006, 84:610-615.
107. Nielsen S.L., Andersen P.L., Koch C., Jensenius J.C., Thiel S. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clin. Exp. Immunol. 1995, 100:219-222.
108. Prohászka Z., Thiel S., Ujhelyi E., Szlávik J., Bánhegyi D., Füst G. Mannan-binding lectin serum concentrations in HIV-infected patients are influenced by the stage of disease. Immunol. Lett. 1997, 58(3):171-175.
109. Garred P., Richter C., Andersen A.B., Madsen H.O., Mtoni I., Svejgaard A., et al. Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scand. J. Immunol. 1997, 46:204-208.
110. Senaldi G., Davies E.T., Mahalingam M., Lu J., Pozniak A., Peakman M., et al. Circulating levels of mannose binding protein in human immunodeficiency virus infection. J. Infect. 1995, 31:145-148.
111. Malik S., Arias M., Di Flumeri C., Garcia L.F., Schurr E. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Immunogenetics 2003, 55:49-52.
112. Catano G., Agan B.K., Kulkarni H., Telles V., Marconi V.C., Dolan M.J., et al. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations. J. Infect. Dis. 2008, 198:72-80.
113. Vallinoto A.C.R., Muto N.A., Alves A.E.M., Machado L.F.A., Azevedo V.N., Souza L.L.B., et al. Characterization of polymorphisms in the mannose-binding lectin gene promoter among human immunodeficiency virus 1 infected subjects. Mem. Inst. Oswaldo Cruz 2008, 103:645-649.
114. Hundt M., Heiken H., Schmidt R.E. Association of low mannose-binding lectin serum concentrations and bacterial pneumonia in HIV infection. AIDS 2000, 14:1853-1854.
115. McBride M.O., Fischer P.B., Sumiya M., McClure M.O., Turner M.W., Skinner C.J., et al. Mannose-binding protein in HIV-seropositive patients does not contribute to disease progression or bacterial infections. Int. J. STD AIDS 1998, 9:683-688.
116. Heggelund L., Mollnes T.E., Ueland T., Christophersen B., Aukrust P., Frøland S.S. Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2003, 32:354-361.
117. Mangano A., Rocco C., Marino S.M., Mecikovsky D., Genre F., Aulicino P., et al. Detrimental effects of mannose-binding lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS progression. J. Infect. Dis. 2008, 198:694-700.
118. Horcajada J.P., Lozano F., Muñoz A., Suarez B., Fariñas-Alvarez C., Almela M., et al. Polymorphic receptors of the innate immune system (MBL/MASP-2 and TLR2/4) and susceptibility to pneumococcal bacteremia in HIV-infected patients: a case-control study. Curr. HIV Res. 2009, 7:218-223.
119. Ameye L., Paesmans M., Thiel S., Jensenius J.C., Aoun M. M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy. Clin. Exp. Immunol. 2012, 167:303-308.
120. Van Breedam W., Pöhlmann S., Favoreel H.W., de Groot R.J., Nauwynck H.J. Bitter-sweet symphony: glycan-lectin interactions in virus biology. FEMS Microbiol. Rev. 2013, (Epub ahead of print).
121. Huskens D., Férir G., Vermeire K., Kehr J.-C., Balzarini J., Dittmann E., et al. Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J. Biol. Chem. 2010, 285:24845-24854.
122. Hoorelbeke B., Huskens D., Férir G., François K.O., Takahashi A., Van Laethem K., et al. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob. Agents Chemother. 2010, 54:3287-3301.
123. (+) cells. Virology 2012, 423:175-186.
124. Mahalingam A., Geonnotti A.R., Balzarini J., Kiser P.F. Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol. Pharm. 2011, 8:2465-2475.
125. Balzarini J., François K.O., Van Laethem K., Hoorelbeke B., Renders M., Auwerx J., et al. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob. Agents Chemother. 2010, 54:1425-1435.
126. Maas J., de Roda Husman A.M., Brouwer M., Krol A., Coutinho R., Keet I., et al. Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS (London, England) 1998, 12(17):2275-2280.
127. Vallinoto A.C.R., Menezes-Costa M.R., Alves A.E.M., Machado L.F.A., de Azevedo V.N., Souza L.L.B., et al. Mannose-binding lectin gene polymorphism and its impact on human immunodeficiency virus 1 infection. Mol. Immunol. 2006, 43(9):1358-1362.
128. Garcia-Laorden M.I., Pena M.J., Caminero J.A., Garcia-Saavedra A., Campos-Herrero M.I., Caballero A., et al. Influence of mannose-binding lectin on HIV infection and tuberculosis in a Western-European population. Mol. Immunol. 2006, 43(14):2143-2150.